Trial Profile
A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEST
- Sponsors Theracos
- 15 Jun 2021 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 16 Jun 2020 Primary endpoint (Change in HbA1c from baseline to week 24) has been met, according to results presented at the 80th Annual Scientific Sessions of the American Diabetes Association